As the inhibition of lncMGC ameliorated DKD-related features in mouse models (Kato et al., 2016), targeting lncRNA-interacting nucleosome remodelers such as SMARCA5 may also be tested as potential new therapeutics for DKD in the future. This evidence concerns the gene SMARCA5 and diabetic kidney disease.